A Budget impact analysis of adalimumab biosimilar: the Italian context

Analisi di budget impact del biosimilare di adalimumab: lo scenario italiano

  • Roberto Ravasio Health Publishing & Services Srl, Milano - Italy
  • Silvio Mazzi Health Publishing & Services Srl, Milano - Italy
  • Maria Esposito UOSD Dermatologia Generale ed Oncologica, Università degli Studi dell’Aquila, L’Aquila - Italy https://orcid.org/0000-0002-4773-6993
  • Gionata Fiorino IBD Center, Dipartimento di Gastroenterologia, Humanitas Research Hospital, Rozzano (MI) and Department of Biomedical Sciences, Humanitas University, Rozzano (MI) - Italy https://orcid.org/0000-0001-5623-2968
  • Alberto Migliore Responsabile UO di Reumatologia, Ospedale San Pietro FBF, Roma and Presidente ISPOR Italy-Rome Chapter, Roma - Italy
Keywords: Adalimumab, Anti-TNF, Biosimilar, cost, Italian NHS


Introduction: Patients’ quality of life impairment together with a heavy burden to the NHS and society are caused by chronic inflammatory diseases. Their treatment substantially improved with the advent of biological drugs (such as adalimumab), but these drugs are very expensive. At present, the patent protection of adalimumab (Humira®) has expired, and a biosimilar (Hyrimoz®) has been approved. Since the biosimilar price is expected to be lower as compared with the originator’s, the present Drug Budget Impact analysis tries to evaluate whether and how much profitable the biosimilar availability will be for the Italian NHS, in terms of cost containment (savings).

Methods and results : The time horizon in the analysis model is five years. The initial overall number of patients treated with adalimumab is estimated (based on the Italian population, the disease prevalence rates, the proportion of patients under treatment and adalimumab market share) and kept constant in time. However, the model assumes that, year by year, patients in treatment with the originator will partly switch to the biosimilar (based on a prudent estimate of the uptake rate), while (due to a bolder estimate) a larger share of naïve patients will directly start with the biosimilar. Thanks to such assumptions, total number of patients treated with adalimumab (separately with the originator and with the biosimilar) is estimated, with the respective total costs.

Conclusions:  According to the present analysis, the availability of the biosimilar would generate cumulated savings (in five years) as high as €260 millions for the Italian NHS.

How to Cite
Ravasio R, Mazzi S, Esposito M, Fiorino G, Migliore A. A Budget impact analysis of adalimumab biosimilar: the Italian context. Abtpn [Internet]. 6May2019 [cited 12Nov.2019];6(1):16-3. Available from: https://journals.aboutscience.eu/index.php/aboutopen/article/view/280
Original research article